Molecular markers related to prognosis of acute myeloid leukemia-review.
- Author:
Chao SUN
1
;
Su-Jiang ZHANG
;
Jian-Yong LI
;
Yun-Feng SHENG
Author Information
1. Department of Hematology, Wuxi People Hospital Affiliated to Nangjing Medical University, Wuxi 214023, Jiangsu Province, Chian.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myeloid, Acute;
diagnosis;
genetics;
Prognosis
- From:
Journal of Experimental Hematology
2009;17(4):1083-1087
- CountryChina
- Language:Chinese
-
Abstract:
Numerous genetic abnormalities which can not be identified by cytogenetic detection (e.g., gene mutations, gene expression abnormalities) have been gradually found, which means that the further molecular classification of AML (acute myeloid leukemia) with distinctive prognosis have arrived. For example, mutations of the transcription factor (CCAAT enhancer binding factor alpha, C/EBPalpha) or nucleophosmin-1 (NPM1) may predict better prognosis, whereas partial tandem duplications of the MLL gene (MLL-PTD), internal tandem duplications of FLT3 (FLT3-ITD) or mutations of WT1 gene confer worse prognosis. This review focuses on the features and relationship of these genetic abnormalities, as well as their influence on the prognosis of AML.
